Amdocs Limited (NYSE: DOX), Endeavour International Co. (NYSE: END), Essex Rental Corporation (NASDAQ: ESSX), Fluidigm Co. (NASDAQ: FLDM) and HCA Holdings Inc. (NYSE: HCA) had ratings on them reiterated by analysts.
Oppenheimer reiterated its “Outperform” rating on Amdocs Limited (DOX). They have a price target of $34.00 on the company.
Endeavour International Co. (END) has a new price target $11.00 placed on by Imperial Capital. They have an “Outperform” rating on the company.
Oppenheimer reiterated its “Outperform” rating on Essex Rental Corporation (ESSX). They have a price target of $8.50 on the company.
Oppenheimer reiterated its “Outperform” rating on Fluidigm Co. (FLDM). They have a price target of $19.00 on the company.
Morgan Stanley (NYSE:MS) reiterated its “Overweight” rating on HCA Holdings Inc. (HCA). They have a price target of $30.00 on the company.
Showing posts with label Amdocs. Show all posts
Showing posts with label Amdocs. Show all posts
Thursday, November 10, 2011
Friday, July 29, 2011
Amdocs (DOX) (DOW) (EQIX) (GLW) (IACI) (LRCX) (LSI) Price Targets Changed
The Dow Chemical Company (NYSE: DOW), Amdocs Limited (NYSE: DOX), Equinix, Inc. (NASDAQ: EQIX), Corning Inc. (NYSE: GLW), InterActiveCorp (NASDAQ: IACI), Lam Research Co. (NASDAQ: LRCX) and LSI Co. (NYSE: LSI) price targets adjusted by analysts.
The Dow Chemical Company (DOW) had its price target lowered by Deutsche Bank (NYSE:DB) from $44.00 to $38.00. They have a “Hold” rating on the company.
Amdocs Limited (DOX) had its price target raised by UBS AG (NYSE:UBS) from $33.00 to $35.00. They have a “Buy” rating on the company.
Equinix, Inc. (EQIX) had its price target raised by Stifel Nicolaus from $120.00 to $130.00. They have a “Buy” rating on the company.
Corning Inc. (GLW) had its price target lowered by Citigroup (NYSE:C) to $18.00. They have a “Hold” rating on the company.
InterActiveCorp (IACI) had its price target raised by Oppenheimer to $53.00.
Lam Research Co. (LRCX) had its price target cut by Stifel Nicolaus from $64.00 to $60.00. They have a “Buy” rating on the company.
LSI Co. (LSI) had its price target raised by Barclays Capital to $8.00. They have an “Equal Weight” rating on the company.
The Dow Chemical Company (DOW) had its price target lowered by Deutsche Bank (NYSE:DB) from $44.00 to $38.00. They have a “Hold” rating on the company.
Amdocs Limited (DOX) had its price target raised by UBS AG (NYSE:UBS) from $33.00 to $35.00. They have a “Buy” rating on the company.
Equinix, Inc. (EQIX) had its price target raised by Stifel Nicolaus from $120.00 to $130.00. They have a “Buy” rating on the company.
Corning Inc. (GLW) had its price target lowered by Citigroup (NYSE:C) to $18.00. They have a “Hold” rating on the company.
InterActiveCorp (IACI) had its price target raised by Oppenheimer to $53.00.
Lam Research Co. (LRCX) had its price target cut by Stifel Nicolaus from $64.00 to $60.00. They have a “Buy” rating on the company.
LSI Co. (LSI) had its price target raised by Barclays Capital to $8.00. They have an “Equal Weight” rating on the company.
Hess (HES) (DOW) (PFCB) (QEP) (TEVA) (DOX) EPS Estimates Changed
Hess Corp. (NYSE: HES), The Dow Chemical Company (NYSE: DOW), P.F. Chang’s China Bistro (NASDAQ: PFCB), QEP Resources (NYSE: QEP), Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) and Amdocs Limited (NYSE: DOX) EPS estimates adjusted.
UBS AG (NYSE:UBS) cut its EPS estimates on Hess Corp. (HES). They have a “Buy” rating and a price target of $90.00 on the company.
UBS AG boosted its EPS estimates on The Dow Chemical Company (DOW). The y have a “Buy” rating and a price target of $46.50 on the company.
Credit Suisse (NYSE:CS) lowered its EPS estimates on P.F. Chang’s China Bistro (PFCB). They have a “Neutral” rating and a price target of $34.00 on the company.
Goldman Sachs (NYSE:GS) raised its EPS estimates on QEP Resources (QEP). They have a “Neutral” rating and a price target of $49.00 on the company.
UBS AG raised its EPS estimates on Teva Pharmaceutical Industries Ltd (TEVA). They have a “Buy” rating and a price target of $64.00 on the company.
Citigroup (NYSE:C) raised its EPS estimates on Amdocs Limited (DOX). They have a “Buy” rating and a price target of $37.00 on the company.
UBS AG (NYSE:UBS) cut its EPS estimates on Hess Corp. (HES). They have a “Buy” rating and a price target of $90.00 on the company.
UBS AG boosted its EPS estimates on The Dow Chemical Company (DOW). The y have a “Buy” rating and a price target of $46.50 on the company.
Credit Suisse (NYSE:CS) lowered its EPS estimates on P.F. Chang’s China Bistro (PFCB). They have a “Neutral” rating and a price target of $34.00 on the company.
Goldman Sachs (NYSE:GS) raised its EPS estimates on QEP Resources (QEP). They have a “Neutral” rating and a price target of $49.00 on the company.
UBS AG raised its EPS estimates on Teva Pharmaceutical Industries Ltd (TEVA). They have a “Buy” rating and a price target of $64.00 on the company.
Citigroup (NYSE:C) raised its EPS estimates on Amdocs Limited (DOX). They have a “Buy” rating and a price target of $37.00 on the company.
Monday, May 2, 2011
Price Targets on (MA) (DOX) (HLS) (LEA) (LO) Raised by Analysts
Amdocs Limited (NYSE: DOX), HealthSouth (NYSE: HLS), Lear Co. (NYSE: LEA), Lorillard Inc. (NYSE: LO) and MasterCard (NYSE: MA) get price targets raised today by analysts.
ThinkEquity raised their price target on Amdocs Limited (DOX) to $32.00. They now have a “hold” rating on the company.
Morgan Stanley (NYSE:MS) raised their price target on HealthSouth (HLS) to $30.00. They have an “overweight” rating on the company.
Goldman Sachs (NYSE:GS) raised their price target on Lear Co. (LEA) to $65.00. They have a “buy” rating on the company.
Goldman Sachs raised their price target on Lorillard Inc. (LO) to $118.00. They now have a “buy” rating on the company.
Goldman Sachs raised their price target on MasterCard (MA) to $310.00. They have a “buy” rating on the company.
ThinkEquity raised their price target on Amdocs Limited (DOX) to $32.00. They now have a “hold” rating on the company.
Morgan Stanley (NYSE:MS) raised their price target on HealthSouth (HLS) to $30.00. They have an “overweight” rating on the company.
Goldman Sachs (NYSE:GS) raised their price target on Lear Co. (LEA) to $65.00. They have a “buy” rating on the company.
Goldman Sachs raised their price target on Lorillard Inc. (LO) to $118.00. They now have a “buy” rating on the company.
Goldman Sachs raised their price target on MasterCard (MA) to $310.00. They have a “buy” rating on the company.
Friday, April 29, 2011
Price Targets on (CERN) (DOX) (EDMC) (EXPE) (FLS) Updated
Price targets on Cerner Corp (NASDAQ: CERN), Amdocs Limited (NYSE: DOX), Education Management Corp (NASDAQ: EDMC), Expedia, Inc. (NASDAQ: EXPE) and Flowserve Corp (NYSE: FLS) were updated today.
JPMorgan Chase & Co. (NYSE:JPM) raised their price target on Cerner Corp (CERN) from $115.00 to $120.00. They have an “overweight” rating on the company.
JPMorgan Chase & Co. raised their price target on Amdocs Limited (DOX) from $33.50 to $36.00.
Goldman Sachs (NYSE:GS) cut their price target on Education Management Corp (EDMC) from $18.00 to $17.00.
UBS AG ((NYSE:UBS) raised their price target on Expedia, Inc. (EXPE) from $25.00 to $27.00. They have a “neutral” rating on the company.
UBS AG raised their price target on Flowserve Corp (FLS) from $134.00 to $138.00. They have a “neutral” rating on the company.
JPMorgan Chase & Co. (NYSE:JPM) raised their price target on Cerner Corp (CERN) from $115.00 to $120.00. They have an “overweight” rating on the company.
JPMorgan Chase & Co. raised their price target on Amdocs Limited (DOX) from $33.50 to $36.00.
Goldman Sachs (NYSE:GS) cut their price target on Education Management Corp (EDMC) from $18.00 to $17.00.
UBS AG ((NYSE:UBS) raised their price target on Expedia, Inc. (EXPE) from $25.00 to $27.00. They have a “neutral” rating on the company.
UBS AG raised their price target on Flowserve Corp (FLS) from $134.00 to $138.00. They have a “neutral” rating on the company.
Thursday, January 27, 2011
Amdocs' (NYSE:DOX) Margins Fall; Revenue, EPS Estimates Lowered
Amdocs Ltd. (NYSE:DOX) had a decent quarter, but weak margins caused the company to miss on the bottom line, resulting in revenue and EPS estimates for 2011, 2012 to be lowered.
FBR says, "Last night, Amdocs reported mixed December results, as the company posted better-than-expected top-line results, sequential increase in backlog, and a miss on the bottom line as margins came in at the low end of expectations in the quarter. Despite the bottom-line miss, we would categorize the December quarter’s performance as respectable, as Amdocs made substantial progress on its previously stated initiatives (emerging market customer win, re-scoping contract with Clearwire, employee productivity programs, and complex customer implementations) and appears to be bulking up its pipeline in the field—positive dynamics that over the long term should help improve the company’s current slow top-line growth trajectory.
"For F2Q11, our revenue estimate of $782.5 million remains unchanged, while we are increasing our pro forma EPS estimate to $0.57 from $0.55 to reflect a lower share count. For FY11, we are lowering our revenue and pro forma EPS estimates to $3.16 billion and $2.24 down from $3.17 billion and $2.27. For FY12, we are lowering our revenue and pro forma EPS estimates to $3.35 billion and $2.51 down from $3.36 billion and $2.56."
FBR Capital reiterates a 'Market Perform' rating on Amdocs Ltd. (DOX), which closed Wednesday at $29.27, gaining $0.44, or 1.53 percent. FBR has a price target of $30 on Amdocs.
FBR says, "Last night, Amdocs reported mixed December results, as the company posted better-than-expected top-line results, sequential increase in backlog, and a miss on the bottom line as margins came in at the low end of expectations in the quarter. Despite the bottom-line miss, we would categorize the December quarter’s performance as respectable, as Amdocs made substantial progress on its previously stated initiatives (emerging market customer win, re-scoping contract with Clearwire, employee productivity programs, and complex customer implementations) and appears to be bulking up its pipeline in the field—positive dynamics that over the long term should help improve the company’s current slow top-line growth trajectory.
"For F2Q11, our revenue estimate of $782.5 million remains unchanged, while we are increasing our pro forma EPS estimate to $0.57 from $0.55 to reflect a lower share count. For FY11, we are lowering our revenue and pro forma EPS estimates to $3.16 billion and $2.24 down from $3.17 billion and $2.27. For FY12, we are lowering our revenue and pro forma EPS estimates to $3.35 billion and $2.51 down from $3.36 billion and $2.56."
FBR Capital reiterates a 'Market Perform' rating on Amdocs Ltd. (DOX), which closed Wednesday at $29.27, gaining $0.44, or 1.53 percent. FBR has a price target of $30 on Amdocs.
Subscribe to:
Posts (Atom)